ZYUS — Zyus Life Sciences Income Statement
0.000.00%
- CA$53.05m
- CA$65.49m
- CA$0.48m
Annual income statement for Zyus Life Sciences, fiscal year end - December 31st, CAD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | R2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | ARS | ARS | ARS | ARS | ARS |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 0 | 0 | 0.298 | 0.351 | 0.481 |
| Cost of Revenue | |||||
| Gross Profit | 0.001 | -0.028 | -0.232 | 0.171 | 0.129 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Depreciation and Amortization | |||||
| Unusual Expense / Income | |||||
| Other Operating Expenses | |||||
| Total Operating Expenses | 0.205 | 0.228 | 19.1 | 44.5 | 35.5 |
| Operating Profit | -0.204 | -0.228 | -18.8 | -44.1 | -35 |
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -0.728 | 0.351 | -24.7 | -48.4 | -35.9 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -0.728 | 0.351 | -24.7 | -42.6 | -33.8 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -0.728 | 0.351 | -24.7 | -42.6 | -33.8 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -0.728 | 0.351 | -24.7 | -42.6 | -33.8 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -0.145 | 0.07 | -0.599 | -0.447 | -0.286 |